Denosumab: An update

Drugs of Today

Volumn 47, Issue 8, 2011, Pages 605-613

  Bogado, Cesar E ^a   Boailchuk, J A ^a   Zanchetta, M B ^a   Massari, F E ^a   Zanchetta, J R ^a  

^a Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; AROMATASE INHIBITOR; DENOSUMAB; METHOTREXATE; PLACEBO; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CALCIUM BLOOD LEVEL; CELLULITIS; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ENDOCARDITIS; HEADACHE; HIP FRACTURE; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; LIMB PAIN; LOADING DRUG DOSE; META ANALYSIS; MORPHOMETRICS; OSTEOCLASTOMA; OSTEOLYSIS; PANCREATITIS; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; VERTEBRA FRACTURE;

ALENDRONATE; ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL; AROMATASE INHIBITORS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND;

EID: 80052758573     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.8.1603507     Document Type: Review

References (34)

1. Pivonka, P., Zimak, J., Smith, D.W. Model structure and control of bone remodeling: A theoretical study. Bone 2008, 43(2): 249-63.
2. Lacey, D.L., Timms, E., Tan, H.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93(2): 165-76.
3. Hsu, H., Lacey, D.L., Dunstan, C.R. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999, 96(7): 3540-5.
4. Li, J., Sarosi, I., Yan, X.Q. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000, 97(4): 1566-71.
5. Simonet, W.S., Lacey, D.L., Dunstan, C.R. et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997, 89(2): 309-19.
6. Hofbauer, L.C., Schoppet, M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292(4): 490-5.
7. Kostenuik, P.J., Nguyen, H.Q., McCabe, J. et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24(2): 182-95.
8. Ominsky, M.S., Kostenuik, P.J., Cranmer, P., Smith, S.Y., Atkinson, J.E. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int 2007, 18(8): 1073-82.
9. Bekker, P.J., Holloway, D.L., Rasmussen, A.S. et al. A singledose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19(7): 1059-66.
10. McClung, M.R., Lewiecki, E.M., Cohen, S.B. et al. Denosumab in post menopausal women with low bone mineral density. N Engl J Med 2006, 354(8): 821-31.
11. Lewiecki, E.M., Miller, P.D., McClung, M.R, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007, 229(12): 1832-41.
12. Miller, P.D., Bolognese, M.A., Lewiecki, E.M. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy. A randomized blinded phase 2 clinical trial. Bone 2008, 43(2): 222-9.
13. Miller, P.D., Wagman, R.B., Peacock, M. et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: Six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab, 2011, 96(2): 394-402.
14. Bone, H.G., Bolognese, M.A., Yuen, C.K., Kendler, D.L., Wang, H., Liu, Y., San Martin, J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93(6): 2149-57.
15. Genant, H.K., Engelke, K., Hanley, D.A, et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47(1): 131-9.
16. Cummings, S.R., San Martin, J., McClung, M.R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(19): 756-65.
17. Brown, J.P., Prince, R.L., Deal, C. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24(1): 153-61.
18. Kendler, D.L., Roux, C., Benhamou, C.L. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25(1): 72-81.
19. Reid, I., Miller, P., Brown, J. et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Miner Res 2010, 25(10): 2256-65.
20. Seeman, E., Delmas, P.D., Hanley, D.A. et al. Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. J Bone Miner Res 2010, 25(8): 1886-94.
21. Smith, M.R., Egerdie, B., Hernández Toriz, N. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361(8): 745-55.
22. Smith, M.R., Saad, F., Egerdie, B. et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009, 182(6): 2670-5.
23. Ellis, G.K., Bone, H.G., Chlebowski, R. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Clin Oncol 2008, 26(30): 4875-82.
24. Fizazi, K., Carducci, M.A., Smith, M.R, et al. A randomized phase III trial of denosumab versus zolendronic acid in patients with bone metastases from castration-resistant prostate cancer: A randomized, double blind study. Lancet 2011, 377(9768): 813-22.
25. Henry, D.H., Costa, L., Goldwasser, F. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29(9): 1125-32.
26. Stopeck, A.T., Lipton, A., Body, J.J. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010, 28(35): 5132-9.
27. Cohen, S.B., Dore, R.K., Lane, N.E. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58(5): 1299-309.
28. Sharp, J.T., Tsuji, W., Ory, P., Harper-Barek, C., Wang, H., Newmark, R. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res 2010, 62(4): 537-44.
29. Deodhar, A., Dore, R.K., Mandel, D. et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res 2010, 62(4): 569-74.
30. Dore, R.K., Cohen, S.B., Lane, N.E. et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010, 69(5): 872-5.
31. Thomas, D., Henshaw, R., Skubitz, K. et al. Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study. Lancet Oncol 2010, 11(3): 275-80.
32. Toulis, A., Anastasilakis, D. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporosis Int 2010, 21(11): 1963-4.
33. Kendler, D.L., McClung, M.R., Freemantle, N. et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporosis Int 2010, 22(6): 1725-35.
34. Jönsson, B., Ström, O., Eisman, J.A., Papaioannou, A., Siris, E.S., Tosteson, A., Kanis, J.A. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporosis Int 2010, 22(3): 967-82.